---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-086454"
form_type: "8-K"
ticker: "NVCT"
cik: "0001875558"
company_name: "Nuvectis Pharma, Inc."
filed_at: "2022-08-05T23:59:59+00:00"
generated_at: "2026-06-24T03:28:57.719516+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Nuvectis reports Q2 2022 net loss of $3.6M; cash $13.6M; pipeline advances

## Summary
- Cash and investments $13.6M at June 30, 2022, up from $5.7M at Dec 31, 2021, driven by IPO.
- Net loss of $3.6M for Q2 2022, narrowed from $5.9M in Q2 2021 due to lower R&D and G&A.
- NXP800 Phase 1a dose-escalation ongoing; Phase 1b expansion expected Q1 2023; FDA cleared IND, U.S. and U.K. enrolling.
- NXP900 IND-enabling studies on track for 2022 completion; preclinical data in medulloblastoma presented.
- Completed $15.9M private placement in August 2022, extending cash runway into H2 2024.

## SEC filing metadata
- accession: 0001104659-22-086454
- form_type: 8-K
- ticker: NVCT
- cik: 0001875558
- company_name: Nuvectis Pharma, Inc.
- filed_at: 2022-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1875558/000110465922086454/0001104659-22-086454-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1875558/000110465922086454/tm2222617d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-086454
- JSON: https://secwatch.observer/filing/0001104659-22-086454.json
- Plain text: https://secwatch.observer/filing/0001104659-22-086454.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.